Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) just unveiled an update.
Shandong Weigao Group Medical Polymer has moved to deepen its investment footprint by setting up a Korea-focused private fund through its indirect wholly owned unit, Wego Healthcare Fund. The vehicle will target small and mid-sized enterprises in Korea and abroad that specialise in open innovation and cross-border expansion involving companies, universities and research institutions.
The fund is planned at KRW52.97 billion, with Wego Healthcare Fund committing KRW15.89 billion, or 30% of total capital, alongside general partners including Wego (HK) and SV Investment. The transaction is classified as a connected one under Hong Kong listing rules, triggering reporting and announcement requirements but not independent shareholder approval, underscoring the group’s use of affiliated structures to pursue overseas growth while staying within compliance thresholds.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
More about Shandong Weigao Group Medical Polymer Co
Shandong Weigao Group Medical Polymer Company Limited is a PRC-incorporated medical products manufacturer listed in Hong Kong. The group operates through subsidiaries including Wego Healthcare Fund and Wego (HK), and focuses on healthcare-related investments and operations across Greater China and overseas markets.
Average Trading Volume: 21,134,478
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.05B
For an in-depth examination of 1066 stock, go to TipRanks’ Overview page.